...
首页> 外文期刊>Human mutation >Lysinuric protein intolerance: update and extended mutation analysis of the SLC7A7 gene.
【24h】

Lysinuric protein intolerance: update and extended mutation analysis of the SLC7A7 gene.

机译:赖氨酸尿酸蛋白不耐受:SLC7A7基因的更新和扩展突变分析。

获取原文
获取原文并翻译 | 示例
           

摘要

Lysinuric protein intolerance (LPI) is an inherited aminoaciduria caused by defective cationic amino acid (CAA) transport at the basolateral membrane of epithelial cells in the intestine and kidney. LPI is caused by mutations in the SLC7A7 gene, which encodes the y(+)LAT-1 protein, the catalytic light chain subunit of a complex belonging to the heterodimeric amino acid transporter family. Coexpression of 4F2hc (the heavy chain subunit) and y(+)LAT-1 induces y(+)L activity (CAA transport). So far a total of 43 different mutations of the SLC7A7 gene, nine of which newly reported here, have been identified in a group of 130 patients belonging to at least 98 independent families. The mutations are distributed along the entire gene and include all different types of mutations. Five polymorphisms within the SLC7A7 coding region and two variants found in the 5'UTR have been identified. A genuine founder effect mutation has been demonstrated only in Finland, where LPI patients share the same homozygous mutation, c.895-2A>T. LPI patients show extreme variability in clinical presentation, and no genotype-phenotype correlations have been defined. This phenotypic variability and the lack of a specific clinical presentation have caused various misdiagnoses. At the biochemical level, the elucidation of SLC7A7 function will be necessary to understand precise disease mechanisms and develop more specific and effective therapies. In this review, we summarize the current knowledge of SLC7A7 mutations and their role in LPI pathogenesis.
机译:赖氨酸尿蛋白不耐受症(LPI)是一种遗传性氨基酸尿症,是由阳离子性氨基酸(CAA)在肠和肾上皮细胞的基底外侧膜上的运输缺陷所引起的。 LPI是由SLC7A7基因中的突变引起的,该基因编码y(+)LAT-1蛋白,该蛋白是属于异二聚氨基酸转运蛋白家族的复合物的催化轻链亚基。 4F2hc(重链亚基)和y(+)LAT-1的共表达诱导y(+)L活性(CAA转运)。到目前为止,已经在属于至少98个独立家庭的130名患者中鉴定出SLC7A7基因的总共43种不同突变,其中9种在这里新报道。突变沿整个基因分布,包括所有不同类型的突变。已经鉴定出SLC7A7编码区内的五个多态性和在5'UTR中发现的两个变体。真正的创始人效应突变仅在芬兰得到证实,芬兰的LPI患者具有相同的纯合突变c.895-2A> T。 LPI患者在临床表现中表现出极大的变异性,并且尚未定义基因型与表型的相关性。这种表型变异和缺乏特定的临床表现已引起各种误诊。在生化水平上,阐明SLC7A7的功能对于理解精确的疾病机制并开发更具体有效的疗法非常必要。在这篇综述中,我们总结了SLC7A7突变的最新知识及其在LPI发病机理中的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号